Literature DB >> 18303933

Improving BP control with combined renin-angiotensin system blockade and thiazide diuretics in hypertensive patients with diabetes mellitus or kidney disease.

Biff F Palmer1.   

Abstract

Most hypertensive patients will require more than one antihypertensive drug to lower BP below target levels. The combination of diuretics with renin-angiotensin system (RAS) antagonists offers several advantages to include additive BP-lowering efficacy and enhanced reductions in urinary protein excretion. Thiazide diuretics are associated with metabolic complications that are particularly evident when used in high doses. When used in combination with RAS blockade, metabolic complications such as hypokalemia are minimized. The avoidance of hypokalemia has been linked to less thiazide-induced glucose intolerance. Patient persistence on therapy is dependent on well tolerated drug combinations.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18303933     DOI: 10.2165/00129784-200808010-00002

Source DB:  PubMed          Journal:  Am J Cardiovasc Drugs        ISSN: 1175-3277            Impact factor:   3.571


  7 in total

Review 1.  Aliskiren: a review of its use as monotherapy and as combination therapy in the management of hypertension.

Authors:  Sean T Duggan; Claudine M Chwieduk; Monique P Curran
Journal:  Drugs       Date:  2010-10-22       Impact factor: 9.546

Review 2.  Losartan/Hydrochlorothiazide: a review of its use in the treatment of hypertension and for stroke risk reduction in patients with hypertension and left ventricular hypertrophy.

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2009-06-18       Impact factor: 9.546

3.  Introducing candesartan 32 mg plus hydrochlorothiazide 25 mg in previously untreated patients with severe essential hypertension.

Authors:  Peter Baumgart; Ingomar Naudts; Gerhard Kiel
Journal:  Pragmat Obs Res       Date:  2011-04-29

4.  Effectiveness of initiating treatment with valsartan/hydrochlorothiazide in patients with stage-1 or stage-2 hypertension.

Authors:  D H Zappe; B F Palmer; D A Calhoun; D Purkayastha; R Samuel; K A Jamerson
Journal:  J Hum Hypertens       Date:  2009-12-10       Impact factor: 3.012

Review 5.  Choice of ACE inhibitor combinations in hypertensive patients with type 2 diabetes: update after recent clinical trials.

Authors:  Gianpaolo Reboldi; Giorgio Gentile; Fabio Angeli; Paolo Verdecchia
Journal:  Vasc Health Risk Manag       Date:  2009

6.  Rationale and study design of the Prospective comparison of Angiotensin Receptor neprilysin inhibitor with Angiotensin receptor blocker MEasuring arterial sTiffness in the eldERly (PARAMETER) study.

Authors:  Bryan Williams; John R Cockcroft; Kazuomi Kario; Dion H Zappe; Pamela Cardenas; Allen Hester; Patrick Brunel; Jack Zhang
Journal:  BMJ Open       Date:  2014-02-04       Impact factor: 2.692

Review 7.  Renal function monitoring in heart failure - what is the optimal frequency? A narrative review.

Authors:  Ahmed Al-Naher; David Wright; Mark Alexander John Devonald; Munir Pirmohamed
Journal:  Br J Clin Pharmacol       Date:  2017-10-22       Impact factor: 4.335

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.